Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

European Journal of Cancer

Volumn 46, Issue 2, 2010, Pages 340-347

  Kummar, Shivaani ^a   Gutierrez, Martin E ^a   Gardner, Erin R ^b   Chen, Xiaohong ^a   Figg, William D ^a   Zajac Kaye, Maria ^a   Chen, Min ^a   Steinberg, Seth M ^a   Muir, Christine A ^a   Yancey, Mary Ann ^a   Horneffer, Yvonne R ^a   Juwara, Lamin ^b   Melillo, Giovanni ^b   Ivy, S Percy ^a   Merino, Maria ^a   Neckers, Len ^a   Steeg, Patricia S ^a   Conley, Barbara A ^a   Giaccone, Giuseppe ^a   Doroshow, James H ^a   Murgo, Anthony J ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

17 DMAG; Clinical trial; Hsp90; Phase I

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRITIS; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUNG INFILTRATE; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZOQUINONES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; YOUNG ADULT;

EID: 72449185268     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.026     Document Type: Article

References (30)

1. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15 (2009) 9-14
2. Banerji U., O'Donnell A., Scurr M., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23 (2005) 4152-4161
3. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8 (2002) S55-S61
4. Nimmanapalli R., O'Bryan E., and Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61 (2001) 1799-1804
5. Ochel H.J., Eichhorn K., and Gademann G. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 6 (2001) 105-112
6. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97 (2000) 10832-10837
7. Schulte T.W., Blagosklonny M.V., Romanova L., et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16 (1996) 5839-5845
8. Smith D.F., Whitesell L., Nair S.C., Chen S., Prapapanich V., and Rimerman R.A. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 15 (1995) 6804-6812
9. Xu W., Mimnaugh E., Rosser M.F., et al. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276 (2001) 3702-3708
10. Blagosklonny M.V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16 (2002) 455-462
11. Glaze E.R., Lambert A.L., Smith A.C., et al. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56 (2005) 637-647
12. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., and Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56 (2005) 126-137
13. Hollingshead M., Alley M., Burger A.M., et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 56 (2005) 115-125
14. Eiseman J.L., Lan J., and Lagattuta T.F. Et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 55 (2005) 21-32
15. Ramanathan R.K., Trump D.L., Eiseman J.L., et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11 (2005) 3385-3391
16. Ramanathan R, Egorin M, Erlichman C, et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, (17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (HSP90), in patients with advanced solid tumors: Final results. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007 [Abstr B212].
17. Simon R., Freidlin B., Rubinstein L., Arbuck S.G., Collins J., and Christian M.C. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89 (1997) 1138-1147
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
19. Chen X., Gardner E.R., Gutierrez M., Kummar S., and Figg W.D. Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 858 (2007) 302-306
20. Pacey S, Wilson R, Walton M, et al. A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007 [abstr PR-6].
21. Lancet J., Gojo I., Baer M., et al. Phase 1, pharmacokinetic (PK), pharmacodynamic (PD) study of of the Hsp-90 inhibitor, KOS-1022 (17-DMAG), in patients with refractory hematological malignancies. J Clin Oncol 24 (2006) 2081
22. Miller K., Rosen L.S., Modi S., et al. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T). J Clin Oncol 25 (2007) 1115
23. Bristol-Myers Squibb. Phase 2 Clinical Trial of Intravenous Alvespimycin [KOS-1022] in Patients With Her2 Positive Breast Cancer. In: ClinicalTrials.gov. NLM Identifier: NCT00780000. http://www.clinicaltrials.gov/ct2/show/NCT00780000 [accessed on March 25, 2009].
24. Bristol-Myers Squibb. Phase 1 Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel. In: ClinicalTrials.gov. NLM Identifier: NCT00803556. http://www.clinicaltrials.gov/ct2/show/NCT00803556 [accessed on March 25, 2009].
25. Holdsworth C.H., Badawi R.D., Manola J.B., et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189 (2007) W324-W330
26. Niu G., Li Z., Cao Q., and Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 36 (2009) 1510-1519
27. Smith-Jones P.M., Solit D., Afroze F., Rosen N., and Larson S.M. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47 (2006) 793-796
28. Eiseman J.L., Guo J., Ramanathan R.K., et al. Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin Cancer Res 13 (2007) 2121-2127
29. Elfiky A., Saif M.W., Beeram M., et al. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: phase I experience. J Clin Oncol 26 (2008) 2503
30. Flaherty K.T., Gore L., Avadhani A.N., et al. First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or QD. J Clin Oncol 26 (2008) 2502